Institution
American College of Cardiology
Education•Washington D.C., District of Columbia, United States•
About: American College of Cardiology is a education organization based out in Washington D.C., District of Columbia, United States. It is known for research contribution in the topics: Health care & Appropriate Use Criteria. The organization has 608 authors who have published 524 publications receiving 54951 citations. The organization is also known as: ACC.
Topics: Health care, Appropriate Use Criteria, Percutaneous coronary intervention, Coronary artery disease, Population
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
Abstract: The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
6,944 citations
••
TL;DR: This document summarizes current capabilities, research and operational priorities, and plans for further studies that were established at the 2015 USGS workshop on quantitative hazard assessments of earthquake-triggered landsliding and liquefaction.
Abstract: ![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1]
![Figure][1
4,975 citations
••
TL;DR: The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) 2005 Guideline Update for Percutaneous Coronary Intervention (PCI) contains changes in the recommendations, along with supporting text.
Abstract: The American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) 2005 Guideline Update for Percutaneous Coronary Intervention (PCI) contains changes in the recommendations, along with supporting text. For the purpose of comparison
2,243 citations
••
American Heart Association1, Centers for Disease Control and Prevention2, American Academy of Family Physicians3, American Congress of Obstetricians and Gynecologists4, Society of Thoracic Surgeons5, American College of Cardiology6, National Institutes of Health7, American College of Physicians8, World Heart Federation9
TL;DR: Major randomized controlled clinical trials such as the Women’s Health Initiative have changed the practice of CVD prevention in women over the past decade and the investment in combating this major public health issue for women has been significant.
Abstract: Substantial progress has been made in the awareness, treatment, and prevention of cardiovascular disease (CVD) in women since the first women-specific clinical recommendations for the prevention of CVD were published by the American Heart Association (AHA) in 1999.1 The myth that heart disease is a “man’s disease” has been debunked; the rate of public awareness of CVD as the leading cause of death among US women has increased from 30% in 1997 to 54% in 2009.2 The age-adjusted death rate resulting from coronary heart disease (CHD) in females, which accounts for about half of all CVD deaths in women, was 95.7 per 100 000 females in 2007, a third of what it was in 1980.3,4 Approximately 50% of this decline in CHD deaths has been attributed to reducing major risk factors and the other half to treatment of CHD including secondary preventive therapies.4 Major randomized controlled clinical trials such as the Women’s Health Initiative have changed the practice of CVD prevention in women over the past decade.5 The investment in combating this major public health issue for women has been significant, as have the scientific and medical achievements.
1,856 citations
••
TL;DR: The American College of Cardiology (ACC) and the American Heart Association (AHA) first published guidelines for the evaluation and management of heart failure (HF) in 1995, and since that time, a great deal of progress has been made in the development of both pharmacological and nonpharmacological approaches to treatment for this common, costly, disabling, and generally fatal disorder.
1,829 citations
Authors
Showing all 609 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eugene Braunwald | 230 | 1711 | 264576 |
Scott M. Grundy | 187 | 841 | 231821 |
Valentin Fuster | 179 | 1462 | 185164 |
Sidney C. Smith | 169 | 467 | 267569 |
David R. Holmes | 161 | 1624 | 114187 |
Elliott M. Antman | 161 | 716 | 179462 |
Christopher P. Cannon | 151 | 1118 | 108906 |
Robert O. Bonow | 149 | 808 | 114836 |
Deepak L. Bhatt | 149 | 1973 | 114652 |
Eric D. Peterson | 143 | 1097 | 84067 |
Roxana Mehran | 141 | 1378 | 99398 |
Jonathan L. Halperin | 133 | 486 | 121655 |
Robert A. Harrington | 124 | 789 | 68023 |
Daniel B. Mark | 124 | 576 | 78385 |
Samuel Z. Goldhaber | 124 | 784 | 69216 |